HRP20070435A9 - Tricyclic-nucleoside compounds for treating viral infections - Google Patents

Tricyclic-nucleoside compounds for treating viral infections

Info

Publication number
HRP20070435A9
HRP20070435A9 HR20070435A HRP20070435A HRP20070435A9 HR P20070435 A9 HRP20070435 A9 HR P20070435A9 HR 20070435 A HR20070435 A HR 20070435A HR P20070435 A HRP20070435 A HR P20070435A HR P20070435 A9 HRP20070435 A9 HR P20070435A9
Authority
HR
Croatia
Prior art keywords
viral infections
tricyclic
nucleoside compounds
treating viral
compounds
Prior art date
Application number
HR20070435A
Other languages
English (en)
Croatian (hr)
Inventor
D. Keicher Jesse
Don Roberts Christopher
Johannes Reinhard Liehr Sebastian
Zheng Xiaoling
Prhavc Marija
Kumar Rajwanshi Vivek
Original Assignee
Genelabs Technologies
Gilead Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Technologies, Gilead Sciences filed Critical Genelabs Technologies
Publication of HRP20070435A2 publication Critical patent/HRP20070435A2/xx
Publication of HRP20070435A9 publication Critical patent/HRP20070435A9/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/22—Pteridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20070435A 2005-02-28 2006-02-28 Tricyclic-nucleoside compounds for treating viral infections HRP20070435A9 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65746305P 2005-02-28 2005-02-28
PCT/US2006/007132 WO2006093987A1 (en) 2005-02-28 2006-02-28 Tricyclic-nucleoside compounds for treating viral infections

Publications (2)

Publication Number Publication Date
HRP20070435A2 HRP20070435A2 (hr) 2008-02-29
HRP20070435A9 true HRP20070435A9 (en) 2008-09-30

Family

ID=36570903

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20070435A HRP20070435A9 (en) 2005-02-28 2006-02-28 Tricyclic-nucleoside compounds for treating viral infections
HR20070436A HRP20070436A2 (hr) 2005-02-28 2006-02-28 Triciklički nukleozidni predlijekovi za liječenjevirusnih infekcija

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20070436A HRP20070436A2 (hr) 2005-02-28 2006-02-28 Triciklički nukleozidni predlijekovi za liječenjevirusnih infekcija

Country Status (18)

Country Link
US (4) US7524825B2 (enExample)
EP (2) EP1853617A1 (enExample)
JP (2) JP2008531703A (enExample)
KR (2) KR20070106781A (enExample)
CN (2) CN101128474A (enExample)
AP (2) AP2007004118A0 (enExample)
AR (1) AR058419A1 (enExample)
AU (2) AU2006218704A1 (enExample)
BR (2) BRPI0607769A2 (enExample)
CA (2) CA2597685A1 (enExample)
EA (2) EA200701849A1 (enExample)
HR (2) HRP20070435A9 (enExample)
IL (2) IL184954A0 (enExample)
MX (2) MX2007010460A (enExample)
NO (2) NO20074613L (enExample)
TW (1) TW200640474A (enExample)
WO (2) WO2006093987A1 (enExample)
ZA (1) ZA200707410B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2537114C (en) 2003-08-27 2012-10-02 Biota, Inc. Tricyclic nucleosides or nucleotides as therapeutic agents
US7524825B2 (en) * 2005-02-28 2009-04-28 Smithkline Beecham Corporation Tricyclic-nucleoside compounds for treating viral infections
US7405204B2 (en) * 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
EP2271351A4 (en) * 2008-04-03 2016-08-31 Spring Bank Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
GB0900914D0 (en) * 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8343983B2 (en) * 2009-03-31 2013-01-01 Arqule, Inc. Substituted pyrazolo-pyrimidine compounds
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
EP2552203B1 (en) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
EP2726610A1 (en) 2011-06-30 2014-05-07 Stella ApS Hcv combination therapy
WO2013033093A1 (en) * 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2639238A1 (en) * 2012-03-15 2013-09-18 Universität Bern Tricyclic nucleosides and oligomeric compounds prepared therefrom
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
BR112014029115A8 (pt) 2012-05-22 2018-04-03 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, uso de um composto ou composição
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
CN104936970A (zh) 2012-10-08 2015-09-23 埃迪尼克斯医药公司 用于hcv感染的2′-氯核苷类似物
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
KR20200060782A (ko) 2013-01-31 2020-06-01 길리애드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PL169273B1 (pl) * 1990-04-04 1996-06-28 Chiron Corp skierowanej przeciw wirusowi zapalenia watroby C PL
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2159639A1 (en) 1993-04-02 1994-10-13 Vincent J. Miles Method for selective inactivation of viral replication
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5861267A (en) 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US5981247A (en) 1995-09-27 1999-11-09 Emory University Recombinant hepatitis C virus RNA replicase
US5759795A (en) 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
KR20000075983A (ko) 1997-03-05 2000-12-26 엘. 데이예를 카렌. 헤파타이티스 ｃ 바이러스 복제를 선택적으로 저해하는 물질을 확인하기 위한 새로운 스크리닝 방법
WO1998043991A1 (en) * 1997-04-02 1998-10-08 Amersham Pharmacia Biotech Uk Limited Tricyclic base analogues
EP1037974B1 (en) * 1997-12-11 2007-10-03 SmithKline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
HUP0400726A3 (en) 2001-01-22 2007-05-29 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2003061385A1 (en) * 2002-01-17 2003-07-31 Ribapharm Inc. Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
EP4032897B1 (en) 2003-05-30 2025-01-29 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
CA2537114C (en) * 2003-08-27 2012-10-02 Biota, Inc. Tricyclic nucleosides or nucleotides as therapeutic agents
US7151089B2 (en) 2003-10-27 2006-12-19 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7157434B2 (en) 2003-10-27 2007-01-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7202223B2 (en) 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7524825B2 (en) 2005-02-28 2009-04-28 Smithkline Beecham Corporation Tricyclic-nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
US20090208457A1 (en) 2009-08-20
AU2006218704A1 (en) 2006-09-08
MX2007010463A (es) 2007-11-08
AP2007004128A0 (en) 2007-08-31
US20060252715A1 (en) 2006-11-09
TW200640474A (en) 2006-12-01
AR058419A1 (es) 2008-02-06
WO2006093987A1 (en) 2006-09-08
CN101142226A (zh) 2008-03-12
WO2006093986A1 (en) 2006-09-08
US20060194749A1 (en) 2006-08-31
JP2008531703A (ja) 2008-08-14
AP2007004118A0 (en) 2007-08-31
NO20074915L (no) 2007-11-20
CA2597685A1 (en) 2006-09-08
EP1853617A1 (en) 2007-11-14
ZA200707410B (en) 2008-10-29
EA200701850A1 (ru) 2008-02-28
IL184955A0 (en) 2007-12-03
US20090253648A1 (en) 2009-10-08
HRP20070436A2 (hr) 2008-02-29
US7534771B2 (en) 2009-05-19
KR20070106767A (ko) 2007-11-05
BRPI0607769A2 (pt) 2009-10-06
CA2597683A1 (en) 2006-09-08
MX2007010460A (es) 2007-11-08
EP1853618A1 (en) 2007-11-14
HRP20070435A2 (hr) 2008-02-29
BRPI0607770A2 (pt) 2009-06-13
EA200701849A1 (ru) 2008-02-28
NO20074613L (no) 2007-11-27
CN101128474A (zh) 2008-02-20
KR20070106781A (ko) 2007-11-05
AU2006218705A1 (en) 2006-09-08
IL184954A0 (en) 2007-12-03
US7524825B2 (en) 2009-04-28
JP2008531704A (ja) 2008-08-14

Similar Documents

Publication Publication Date Title
HRP20070435A9 (en) Tricyclic-nucleoside compounds for treating viral infections
DE602007006796D1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
CY1111423T1 (el) Αναστολεις ns5b hcv
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
EA201290993A1 (ru) Нуклеозидфосфорамидаты
EA200700243A1 (ru) Способы лечения гепатита с
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
EA200901241A1 (ru) Соединения для лечения гепатита с
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
NI200900069A (es) Inhibidores de la proteasa ns3 del hcv
EA201100390A1 (ru) Соединения для лечения гепатита с
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
WO2008008907A3 (en) Antiviral agents
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
EA201000051A1 (ru) Противовирусные соединения, композиции и способы использования
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
AR057641A1 (es) Compuestos 5- nitro - nucleosidos para tratar infecciones virales
UA95990C2 (en) Hcv ns3 protease inhibitors
UY28580A1 (es) Compuestos nucleosidicos para el tratamiento de infecciones virales
MY142331A (en) Bicyclic heteroaryl derivatives for treating viruses

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A9IS Complete republication of an hr-a document
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081223

Year of fee payment: 4

OBST Application withdrawn